Form 10-Q INOVIO PHARMACEUTICALS, For: Mar 31

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. MSFT
6. NVDA
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to Form 10-Q INOVIO PHARMACEUTICALS, For: Mar 31

Stifel Keeps Inovio Pharma (INO) at 'Buy' Following Q1 Report; Cash Position Expected to Remain Firm on New Grants

May 9, 2016 12:44 PM EDT

Stifel affirms Inovio Pharma (Nasdaq: INO) with a Buy rating and $13 price target after the copany reported Q1 EPS of ($0.11), which was $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $8.1 million versus the consensus estimate of $4.75 million.

Analyst Thomas Shrader commented: Inovio... More

Inovio Pharma (INO) Tops Q1 EPS by 3c; Provides Corp. Update

May 9, 2016 7:52 AM EDT

Inovio Pharma (NASDAQ: INO) reported Q1 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $8.1 million versus the consensus estimate of $4.75 million.

Corporate Update

Clinical Development

Subsequent to the quarter, Inovio held constructive meetings with both FDA (end of phase II) and European Medicines Agency (EMA) providing an affirmative path forward toward an indication for VGX-3100 to treat HPV-16/18-related... More